{
    "clinical_study": {
        "@rank": "18274", 
        "arm_group": [
            {
                "arm_group_label": "ADASUVE 10 mg 2 doses 2 hours apart", 
                "arm_group_type": "Experimental", 
                "description": "ADASUVE 10 mg 2 doses 2 hours apart + Oral Placebo"
            }, 
            {
                "arm_group_label": "Inhaled placebo + Oral placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Staccato Placebo 2 doses 2 hours apart + Oral Placebo"
            }, 
            {
                "arm_group_label": "Oral moxifloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Staccato Placebo 2 doses 2 hours apart + Oral moxifloxacin 400 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "It has been shown in a pre-marketing clinical study that clinically relevant QT prolongation\n      does not appear to be associated with a single dose of ADASUVE. The potential risk of QTc\n      prolongation following repeat dosing is unknown. Therefore the current study will assess the\n      potential effects on the QT interval of 2 consecutive doses of ADASUVE administered 2 hours\n      apart, in relation to placebo and an active control in healthy volunteers.\n\n      The study hypothesis H0: Placebo-subtracted max mean dQTc > 10 msec"
        }, 
        "brief_title": "QT/QTc Study of 2 Doses of ADASUVE\u00ae", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects between the ages of 18 to 65 years, inclusive.\n\n          -  Body mass index (BMI) \u226518 and \u226432.\n\n          -  Subjects who are willing and able to comply with the study schedule and requirements,\n             and stay at the CRU for a 4-day period and 2 consecutive 3-day periods.\n\n          -  Subjects who speak, read, and understand English and/or Dutch and are willing and\n             able to provide written informed consent on an IEC approved form prior to the\n             initiation of any study procedures.\n\n          -  Subjects who are in good general health prior to study participation\n\n          -  Female or male participants who agree to use a medically acceptable and effective\n             birth control method\n\n        Exclusion Criteria:\n\n          -  Subjects who regularly consume large amounts of xanthine-containing substances (\u2265 5\n             cups of coffee/day).\n\n          -  Subjects who have taken prescription or nonprescription medication within 5 days of\n             Visit 2.\n\n          -  Subjects who have had an acute illness within the last 5 days of Visit 2.\n\n          -  Subjects who have smoked tobacco within the last 30 days or who have a positive\n             cotinine test.\n\n          -  Subjects who have a history of HIV, anti-HCV or HbsAg positivity.\n\n          -  Subjects who have a history within the past 2 years of drug or alcohol dependence or\n             abuse as defined by DSM-IV.\n\n          -  Subjects who test positive for alcohol or have a positive urine drug screen.\n\n          -  Subjects who have a history of allergy or intolerance to loxapine or amoxapine or\n             history of bronchospasm following inhaled loxapine treatment.\n\n          -  Subjects who have an ECG abnormality.\n\n          -  Subjects who have hypotension, or hypertension.\n\n          -  Subjects who have a history of unstable angina, syncope, coronary artery disease,\n             myocardial infarction, congestive heart failure, transient ischemic attack, history\n             of convulsions or other neurological disorder.\n\n          -  Subjects who have a current history of asthma, chronic obstructive lung disease, or\n             any other lung disease associated with bronchospasm.\n\n          -  Subjects who use medications to treat airways disease, such as asthma or COPD.\n\n          -  Subjects who have any acute respiratory signs/symptoms (e.g., wheezing).\n\n          -  Female subjects who have a positive pregnancy test at screening or at admission to\n             any of the treatment visits, or are breastfeeding.\n\n          -  Subjects who have received an investigational drug within 60 days prior to the\n             Screening Visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854710", 
            "org_study_id": "AMDC-204-407", 
            "secondary_id": "204-407"
        }, 
        "intervention": [
            {
                "arm_group_label": "ADASUVE 10 mg 2 doses 2 hours apart", 
                "description": "inhaled loxapine", 
                "intervention_name": "ADASUVE 10 mg 2 doses 2 hours apart", 
                "intervention_type": "Drug", 
                "other_name": "Staccato Loxapine"
            }, 
            {
                "arm_group_label": "Oral moxifloxacin", 
                "intervention_name": "Oral moxifloxacin 400 mg", 
                "intervention_type": "Drug", 
                "other_name": "AVELOX"
            }, 
            {
                "arm_group_label": [
                    "Inhaled placebo + Oral placebo", 
                    "Oral moxifloxacin"
                ], 
                "description": "Inhaler with no drug in it to mimic the ADASUVE inhaler", 
                "intervention_name": "Staccato Placebo 2 doses 2 hours apart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ADASUVE 10 mg 2 doses 2 hours apart", 
                    "Inhaled placebo + Oral placebo"
                ], 
                "description": "placebo capsule to mimic moxifloxacin 400 mg", 
                "intervention_name": "Placebo (for moxifloxacin)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Loxapine", 
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ADASUVE", 
            "inhaled loxapine", 
            "thorough QT/QTc study"
        ], 
        "lastchanged_date": "July 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands"
                }, 
                "name": "PRA International"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "Thorough QT/QTc Study of 2 Doses of ADASUVE\u00ae in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "PRA International", 
            "last_name": "Teresa Nunes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "based upon time-matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time-matched placebo subtraction for ADASUVE treatment at 12 post-inhalation times", 
            "measure": "Maximum effect of ADASUVE on cardiac repolarization (QTc interval duration) at the maximum clinical dose compared to placebo", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854710"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Linear and nonlinear regression of QTcI versus time matched serum loxapine concentrations", 
                "measure": "QTc versus loxapine concentration", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Numbers and percents of subjects exceeding QTcI > 450 ms, QTcI > 480 ms and QTcI > 500 ms; QTcI increase from baseline > 30 ms; QTcI increase from baseline > 60 ms.", 
                "measure": "Categorical analyses of QTcI outliers", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Alexza Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexza Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}